Mianserine Zentiva (Mianserin Hydrochloride)

Mianserin works by blocking presynaptic α2‑adrenergic receptors and serotonin 5‑HT2 receptors. This antagonism increases the release of norepinephrine and serotonin, enhancing neurotransmission in pathways that regulate mood and alleviating depressive symptoms.

The dosage of Mianserine Zentiva is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, response to therapy and tolerability. Patients should follow the prescribing physician’s instructions and not adjust the dose on their own.

Safety data for mianserin in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mianserine belongs to the tetracyclic class, differing from selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) in its receptor profile. It tends to cause less sexual dysfunction than SSRIs but may be associated with sedation and weight gain, making its risk‑benefit profile distinct for individual patients.

Mianserine Zentiva should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, light and excessive heat to maintain its stability and potency throughout its shelf life.

Mianserine Zentiva is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse reactions, although rare, include agranulocytosis, seizures and severe hypotension. Patients should be monitored for signs of infection, neurological changes or sudden drops in blood pressure, and should seek immediate medical attention if such symptoms occur.

Mianserine Zentiva is contraindicated in individuals with known hypersensitivity to mianserin or any excipients, and in patients currently taking monoamine oxidase inhibitors (MAOIs). Caution is also advised for those with severe liver impairment, uncontrolled hypertension or a history of seizures.